hepatocellular carcinoma
Conditions
Interventions
Miriplatin TACE
Epirubicin TACE
Sponsors
Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically proven or clinically diagnosed hepatocellular carcinoma. Number of tumors are up to 10. 2) Patients who have a recurrence after Epirubicin TACE. 3) Patients who fulfill of the inclusion criteria below. 1. PLT >=30000/mm3 2. T.Bil <=3.0mg/dl 3. Cr <=1.5mg/dl 4) Performance status (ECOG) of 0-2 5) The patient without anamunesis of the hypersensitivity to drug utilization 6) Without tumor thrombosis in main portal branch or portal trunk 7) Child-Pugh class A or B. 8) Without pregnant, lactating women or women with suspected pregnancy 9) Patients who were provided written informed consent
Exclusion criteria
Exclusion criteria: 1) Extrahepatic metastasis 2) Patients with active double cancer. 3) Patients with remarkable findings of A-P shunt and/or A-V shunt. 4) Patients with serious allergic symptoms with iodine. 5) Pregnant, lactating women or women with suspected or desired pregnancy 6) Patients who are concluded to be inappropriate to participate in this study by their physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor response | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, progression free survival, time to treatment failure, tumor marker change, safety | — |
Countries
Japan
Contacts
Public ContactTetsuya Minami
Kanazawa University Hospital Department of Radiology
Outcome results
None listed